Visionary Investigators Network

Running trials

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· Source

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· Source

• Recruiting

  ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  NCT07284420· Phase 2· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· Source

• Recruiting

  A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  NCT06798012· Phase 2· Source

• Recruiting

  A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

  NCT06909214· Phase 4· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Source

• Recruiting

  Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

  NCT06584357· Source

• Recruiting

  Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

  NCT05518578· Phase 2· Source

• Active, not recruiting

  Clinical Trial on Agitation in Alzheimer's Dementia

  NCT05543681· Phase 2· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myasthenia gravis4 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Epilepsy2 recruiting
• Alzheimer disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

  NCT06637072· Phase 4· Source

• Completed

  A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

  NCT06538116· Phase 2· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

  NCT05979415· Phase 2· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Source

• Terminated

  PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

  NCT03655236· Phase 2· Source